ArticleScientific reports2025
Antineoplastic effect of anastrozole-loaded polymer nanocapsules on malignant human breast cancer cells (MCF-7).
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The fundamental reason in chemotherapy’s failure to treat breast cancer (BC) is therapy confrontation. BC is frequently treated with anastrozole (ANZ), a non-steroidal aromatase inhibitor. But, its incomplete bioavailability and side effects necessitate improved drug delivery system. This study intended to increase the cytotoxicity impact of ANZ by loading it in polymeric nanocapsules (ANZ-PNCs) in MCF-7 via increasing IC50 and apoptosis. Polymeric nanocapsules (PNCs) prepared using an emulsion-based method, And particle dimension and morphology were characterized via field emission scanning electron microscopy (FESEM) and dynamic light scattering (DLS). UV-vis spectroscopy was used to measure the encapsulation efficiency (E.E.%) of ANZ-loaded PNCs. Apoptosis induction was assessed by Flow Cytometry, Anexxin V-FITC/PI labeling, BAX, P53, BCL-2 genes using real-time PCR, and caspase-3,-8, and − 9 activity assays. The synthesized ANZ-PNCs showed a uniform spherical shape with an average size 10 nm. Drug loading content (LC%) was 3.2 ± 0.4 and the EE% was 74.6 ± 2.3. In vitro cytotoxicity assay by MTT test revealed ANZ-loaded PNCs (9 µg/mL) achieved similar therapeutic effects than free ANZ (48 µg/mL). BAX and P53 expression significantly increased (3.3 (P < 0.01) and 2.8 (P < 0.05) times, respectively); contrarywise, BCL-2 was decreased versus untreated controls. Caspase-3, and − 9 levels (P < 0.001) and caspase − 8 (P < 0.01) were elevated after ANZ-loaded PNCs administration. Morphological studies revealed nuclear fragmentation and cell shape changes after giving 9 µg/mL ANZ-PNCs, indication apoptosis induction. Strong matches, the ANZ loaded PNCs can be used to deliver ANZ for breast cancer chemotherapy of breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.